family with sequence similarity 167 member BGenealiases: C1orf90 · DIORA-2
Q-omics provides the consensus-scored FAM167B profile across patient tissues and cancer cell-line models. FAM167B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM167B is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, FAM167B RNA expression shows 16,058 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KICH, and TGCT as cancer lineages where FAM167B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM167B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM167B survival associations across molecular data types. FAM167B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM167B RNA expression–survival associations across cancer types. High FAM167B expression shows unfavorable associations in KIRP, COAD and MESO, but favorable associations in KIRC, THYM and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM167B RNA expression.
This table summarizes FAM167B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM167B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM167B shows lower tumor expression in KICH, KIRP, LUAD and LUSC and higher tumor expression in HNSC and COAD. The KICH box plot shows higher FAM167B RNA expression in normal versus tumor tissue (log2 FC = −2.767, t-test p < 0.001).
This table shows molecular features associated with FAM167B in patient tissues and cancer cell lines. In patient samples, FAM167B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM167B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
